Taiwan’s Central Epidemic Command Center (CECC) announced on Saturday (May 30) that Taiwan Food and Drug Administration (TFDA) has allowed the import of the anti-viral drug remdesivir, but only for the treatment of severe cases of the coronavirus disease (COVID-19).
The TFDA’s decision was based on the needs of domestic public health and balance of risks. The CECC reported that remdesivir is approved as there were evidences indicating its positive effect and safety in treating COVID-19 patients. The drug has also been gradually approved for use in the international community.
According to officials, the country is following the example of the United States and Japan, which approved emergency use of the drug against the coronavirus in early May.
The approval of the importation of remdesivir can ensure patients’ rights to receive the medical treatment and proactively respond to the possible developments of the COVID-19 outbreak.
The CECC said Remdesivir treatment will only be allowed to last for 10 days, with close monitoring for side effects and registration required for each case while the amount of scientific evidence that the drug works against the coronavirus is as yet insufficient.
No comments:
Post a Comment